QCG
TBPH icon

Quadrant Capital Group’s Theravance Biopharma TBPH Stock Holding History

Quadrant Capital Group’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-335
Closed -$2.99K – 2484
2025
Q1 		$2.99K Sell
335
-697
-68% -$6.49K ﹤0.01% 2450
2024
Q4 		$9.71K Buy
1,032
+806
+357% +$7.33K ﹤0.01% 2136
2024
Q3 		$1.82K Sell
226
-763
-77% -$6.61K ﹤0.01% 2515
2024
Q2 		$8.39K Buy
989
+242
+32% +$2.18K ﹤0.01% 2171
2024
Q1 		$6.7K Buy
747
+461
+161% +$4.27K ﹤0.01% 2240
2023
Q4 		$3.21K Buy
286
+234
+450% +$2.35K ﹤0.01% 2378
2023
Q3 		$449 Hold
52
– – ﹤0.01% 2582
2023
Q2 		$539 Hold
52
– – ﹤0.01% 2561
2023
Q1 		$565 Sell
52
-76
-59% -$804 ﹤0.01% 2593
2022
Q4 		$1.44K Sell
128
-7
-5% -$74 ﹤0.01% 2478
2022
Q3 		$1K Hold
135
– – ﹤0.01% 2566
2022
Q2 		$1K Sell
135
-39
-22% -$359 ﹤0.01% 2452
2022
Q1 		$2K Hold
174
– – ﹤0.01% 2197
2021
Q4 		$2K Buy
174
+137
+370% +$1.19K ﹤0.01% 2186
2021
Q3 		$0 Buy
37
+12
+48% +$134 ﹤0.01% 2643
2021
Q2 		$0 Buy
+25
New +$469 ﹤0.01% 2555
2020
Q2 		– Sell
-1,693
Closed -$39K – 2390
2020
Q1 		$39K Buy
1,693
+8
+0.5% +$200 0.01% 995
2019
Q4 		$43K Hold
1,685
– – 0.01% 1411
2019
Q3 		$32K Buy
+1,685
New +$34K ﹤0.01% 1417

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Quadrant Capital Group's TBPH Position: Q2 2025 in Review

Quadrant Capital Group sold out of Theravance Biopharma (TBPH) in Q2 2025, closing a stake of 335 shares — an estimated $2.99K sold.

Quadrant Capital Group first reported a position in TBPH in Q3 2019 and held it in 19 quarters. The position peaked at $43K in Q4 2019. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

  • Quadrant Capital Group reported no remaining Theravance Biopharma position as of Q2 2025 after selling out during the quarter.
  • Quadrant Capital Group sold 335 Theravance Biopharma shares in Q2 2025, an estimated $2.99K.
  • Quadrant Capital Group first reported a position in Theravance Biopharma in Q3 2019 and held it in 19 quarters.
  • Quadrant Capital Group's Theravance Biopharma position peaked at $43K in Q4 2019.
  • 135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.